Method for detecting related substances in desloratadine raw material or preparation thereof

By using gradient program of phosphate buffer combined with methanol and acetonitrile in high performance liquid chromatography, the problem of difficulty in separation of deloratadine impurities is solved, and accurate quantity detection of drug quality control is achieved, which simplifies operation and reduces The cost.

CN119000975APending Publication Date: 2024-11-22YANGTZE RIVER PHARM GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310553383.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The structures of deloratadine-related impurities have similar polarities, making it difficult to effectively separate and accurately quantify the amount under conventional chromatography conditions, affecting drug quality control.

Method used

High performance liquid chromatography, using phosphate buffer, combined with methanol and acetonitrile, combined with reverse phase chromatography column and specific gradient procedures for elution, to achieve effective between deloratadine and impurities and between impurities and impurities Separate and avoid using ion pair reagents to reduce baseline differences and column losses.

Benefits of technology

It realizes accurate quantity detection of impurities in deloratadin raw materials or their preparations, simplifies experimental operations, reduces costs, improves the accuracy and reliability of the detection, and is suitable for drug quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119000975A_ABST
    Figure CN119000975A_ABST
Patent Text Reader

Abstract

The invention relates to a method for detecting related substances in a desloratadine raw material or a preparation thereof, which is characterized in that a phosphate buffer solution is matched with methanol and acetonitrile, and elution is carried out by combining a reversed-phase chromatographic column and a specific gradient program, so that effective separation between desloratadine and impurities as well as between the impurities can be realized; and accurate quantification can be realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of drug analysis and quality control, and in particular to a method for detecting related substances in a desloratadine raw material or a desloratadine preparation. Background Art

[0002] Desloratadine, chemical name is 8-chloro-6,11-dihydro-11-(4-piperidinyl)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine. Desloratadine is a long-acting tricyclic histamine antagonist with selective antagonism to H1 receptors. It is used to relieve systemic and local symptoms of chronic idiopathic urticaria and allergic rhinitis. Desloratadine can inhibit histamine release from human mast cells in vitro. Radiolabeled tissue distribution studies in rats and guinea pig radioligand H1 receptor binding studies have shown that desloratadine is not easy to pass through the blood-brain barrier. The chemical structure of desloratadine is:

[0003]

[0004] The structures of the related impurities of desloratadine are similar in polarity. Under conventional chromatographic conditions, when using conventional chromatographic columns such as C8 and C18, it is difficult to separate them and it is difficult to achieve effective separation and accurate quantification of all impurities.

[0005] Therefore, it is particularly important to find a detection method that can effectively separate and accurately quantify the related substances in desloratadine raw materials or its preparations for the quality control of desloratadine. Summary of the invention

[0006] The purpose of the present invention is to overcome the defects of the prior art and provide a method for detecting related substances in a desloratadine raw material or a preparation thereof. The method selects a phosphate buffer solution in combination with methanol and acetonitrile, and combines a reverse phase chromatographic column and a specific gradient program for elution, thereby achieving effective separation between desloratadine and impurities and between impurities, and accurate quantification.

[0007] In order to achieve the above objectives, the present invention provides the following technical solutions.

[0008] A method for detecting related substances in a desloratadine raw material or a desloratadine preparation, using high performance liquid chromatography for qualitative and / or quantitative detection, wherein the detection conditions include:

[0009] Chromatographic column: reverse phase column;

[0010] Mobile phase: mobile phase A and mobile phase B, wherein the mobile phase A is a phosphate buffer solution, and the mobile phase B is a mixed solution of methanol and acetonitrile for gradient elution.

[0011] The detection method of the present invention can realize effective separation of related substances in a desloratadine raw material or a preparation thereof without using an ion pair reagent (such as sodium dodecyl sulfate, sodium heptane sulfonate, sodium pentane sulfonate, sodium hexane sulfonate, tetrahydrofuran, etc.), and can avoid the problems of poor baseline, unstable chromatography, large loss of chromatographic column, etc. caused by using an ion pair reagent; there is no need to use a reference substance external standard for quantification, and the solution preparation is simple; therefore, the detection method of the present invention can also save experimental costs.

[0012] In some embodiments of the present invention, the elution conditions are:

[0013]

[0014] In some embodiments of the present invention, the detection method uses the following elution program for gradient elution:

[0015]

[0016] In some embodiments of the present invention, the detection method uses the following elution program for gradient elution:

[0017]

[0018] By optimizing the elution degree, the effective separation of related substances in the desloratadine raw material or its preparation can be better achieved, making the quantification more accurate.

[0019] In some embodiments of the present invention, in the gradient elution program, the time is limited to 35 to 45 minutes, and other elution programs may be included thereafter.

[0020] For example, the mobile phase adopts an isocratic elution program after 35-45 minutes, with mobile phase A 75-85 volume%, and mobile phase B 25-15 volume%. Preferably, the following isocratic elution program is adopted after 40 minutes: mobile phase A 75-82 volume%, mobile phase B 25-18 volume%;

[0021] Preferably, the mobile phase can adopt the following isocratic elution program after 40 min:

[0022]

[0023] In some embodiments of the present invention, the volume ratio of methanol to acetonitrile in the mobile phase B may be (1-3): (3-1), preferably (1-2): (3-1), and most preferably 1: 1. By optimizing the mobile phase B, the effective separation of related substances in the desloratadine raw material or its preparation can be better achieved.

[0024] In some embodiments of the present invention, the pH value of the phosphate buffer solution may be 1.5 to 2.5, for example, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4 or 2.5, preferably 1.9-2.1, and most preferably 2.00. The inventors found that as the pH increases, the retention of impurities (peak time) increases, and the response of some impurities is relatively low. In addition, when the mobile phase contains organic amines, the organic amines are highly alkaline and easily exceed the tolerance range of the chromatographic column. The present invention selects a pH range of 1.5-2.5, which will not affect the chromatographic column and extend its service life.

[0025] In some embodiments of the present invention, the phosphate buffer solution may include one or more of potassium dihydrogen phosphate solution, sodium dihydrogen phosphate solution, dipotassium hydrogen phosphate solution, and disodium hydrogen phosphate solution.

[0026] In some embodiments of the present invention, the concentration of the phosphate buffer solution may be 0.005-0.015 mol / L, for example, 0.005 mol / L, 0.006 mol / L, 0.007 mol / L, 0.008 mol / L, 0.009 mol / L, 0.01 mol / L, 0.011 mol / L, 0.012 mol / L, 0.013 mol / L, 0.014 mol / L or 0.015 mol / L, and most preferably 0.01 mol / L.

[0027] In some embodiments of the present invention, the mobile phase A is a mixture of the phosphate buffer solution and an organic amine. Preferably, the organic amine can be selected from one or more of triethylamine, tetrabutylammonium hydrogen sulfate, tetrabutylammonium bromide, tetrabutylammonium hydroxide or perfluorotriethylamine. Preferably, the volume ratio of the organic amine to the phosphate buffer solution is (1ml-20ml):1L, for example, 1ml:1L, 5ml:1L, 10ml:1L, 15ml:1L or 20ml:1L, most preferably 10ml:1L. Adding an organic amine to the phosphate buffer solution can weaken the strong interaction between the alkaline solute and the residual silanol group, and reduce or eliminate the peak tailing phenomenon. Triethylamine is preferred. The detection wavelength of the present application is 280nm, and triethylamine has a strong absorption peak at 230nm, so selecting triethylamine as a tailing inhibitor will not interfere with sensitivity.

[0028] In some embodiments of the present invention, the reverse phase chromatographic column used in the detection method may be a C8 chromatographic column, a C18 chromatographic column or other equivalent chromatographic columns. In some specific embodiments, the chromatographic column used has a low silanol activity and is an alkaline deactivated thermoelectric chromatographic column with similar selectivity to the C18 chromatographic column. The specifications of the chromatographic column may be 4.6 mm × 250 mm, 3 μm to 5 μm, preferably 5 μm. The chromatographic column is preferably a Thermo BDS Hypersil C8 chromatographic column.

[0029] In some embodiments of the present invention, the column temperature may be 30°C to 45°C, for example, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C or 45°C, preferably 38°C to 42°C.

[0030] In some embodiments of the present invention, the flow rate may be 0.5 ml / min to 1.5 ml / min, for example, 0.5 ml / min, 0.6 ml / min, 0.7 ml / min, 0.8 ml / min, 0.9 ml / min, 1.0 ml / min, 1.1 ml / min, 1.2 ml / min, 1.3 ml / min, 1.4 ml / min or 1.5 ml / min, preferably 1.0 ml / min.

[0031] In some embodiments of the present invention, the injection volume may be 20 to 60 μl, preferably 30 to 50 μl, and more preferably 40 μl.

[0032] In some embodiments of the present invention, the detector may be a UV detector.

[0033] In some embodiments of the present invention, the detection wavelength may be 280 nm.

[0034] In some embodiments of the present invention, the related substances in the desloratadine raw material or its preparation include one or more of the following compounds:

[0035]

[0036] The detection method of the invention can realize the effective separation between desloratadine and the above 8 impurities and between impurities, and has good separation effect.

[0037] In some embodiments of the present invention, the detection method further comprises preparing one or more of the following solutions:

[0038] Blank excipient solution: Accurately weigh the excipients in the desloratadine oral solution except desloratadine, and dissolve them in water to make up the volume;

[0039] Prepare the test solution: accurately measure an appropriate amount of desloratadine oral solution, dilute with solvent to obtain the test solution, wherein the concentration of desloratadine is 0.01 mg / ml to 2 mg / ml, preferably 0.1 mg / ml to 1 mg / ml, and more preferably 0.2 mg / ml;

[0040] Prepare the self-control solution: accurately measure an appropriate amount of the test solution, add a solvent to dilute it, and then obtain the self-control solution, wherein the concentration of desloratadine is 0.05-10 μg / ml, preferably 1 μg / ml;

[0041] Preparation of system suitability solution: Prepare by destruction, accurately weigh an appropriate amount of desloratadine reference substance, add propylene glycol to dissolve (if necessary, ultrasonically dissolve) and dilute to prepare a solution containing about 0.1 to 10 mg of desloratadine per 1 ml, and let stand for 0.1 to 24 hours as a system suitability solution stock solution; accurately measure an appropriate amount of the system suitability solution stock solution, add a solvent to quantitatively dilute to prepare a solution containing about 0.01 mg / ml to 2 mg / ml of desloratadine per 1 ml, as a system suitability solution; preferably, accurately weigh an appropriate amount of desloratadine reference substance, add propylene glycol to dissolve (if necessary, ultrasonically dissolve) and dilute to prepare a solution containing about 1 mg per 1 ml, let stand for 2 hours, as a system suitability solution stock solution; accurately measure an appropriate amount of the system suitability solution stock solution, add a solvent to quantitatively dilute to prepare a solution containing about 0.2 mg of desloratadine per 1 ml;

[0042] The solvent is a mixed solution of methanol and water. Preferably, the volume ratio of methanol to water is (40-60):(60-40), preferably (45-55):(55-45), and more preferably 50:50.

[0043] In some embodiments of the present invention, the detection method uses the principal component self-control method without adding a correction factor to calculate the impurity content.

[0044] Compared with the prior art, the present invention has the following beneficial effects:

[0045] The invention provides a detection method for related substances in a desloratadine raw material or a preparation thereof. The detection method selects a phosphate buffer solution in combination with methanol and acetonitrile, combines a reverse phase chromatographic column and a specific gradient program for elution, can realize effective separation between desloratadine and eight impurities and between impurities, overcomes the problems of poor peak shape, unstable chromatography, loss of chromatographic column, etc. caused by using ion pair reagents (such as sodium dodecyl sulfate, sodium heptane sulfonate, tetrahydrofuran, etc.) to separate compounds with similar polarity, and overcomes the problems of needing to match a phosphate buffer system with a plurality of organic solvents, having fewer types of separated impurities, needing to use an impurity external standard for quantification, and having high cost, and the like. The preparation operation is simple, and the detection result is accurate and reliable. The method is currently the most advanced method for analyzing desloratadine with the lowest cost, is helpful for further quality research on the product, and provides a reliable basis for product development and detection and release.

[0046] The detection method of the present invention has good system applicability and specificity, and its linearity, accuracy and precision all meet the requirements, and has good durability. It can achieve the purposes of effective separation, accurate quantification and cost saving, and can better control the quality of desloratadine raw materials and preparations thereof. The method is novel, has low cost and can be promoted for use. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 It is the detection chromatogram of chromatographic condition 1.

[0048] Figure 2 It is the detection chromatogram of chromatographic condition 2.

[0049] Figure 3 This is the detection chromatogram of chromatographic condition 3.

[0050] Figure 4 This is the detection chromatogram of chromatographic condition 4.

[0051] Figure 5 This is the detection chromatogram of chromatographic condition 5.

[0052] Figure 6 This is the detection chromatogram of chromatographic condition 6.

[0053] Figure 7 This is the detection chromatogram of chromatographic condition 7.

[0054] Figure 8 It is the detection chromatogram of chromatographic condition 8.

[0055] Fig. 9 It is the detection chromatogram of chromatographic condition 9.

[0056] Fig.10 It is the detection chromatogram of chromatographic condition 10.

[0057] Fig.11It is the detection chromatogram of chromatographic condition 11.

[0058] Fig.12 It is the detection chromatogram of chromatographic condition 12.

[0059] Fig.13 This is the detection chromatogram of chromatographic condition 13.

[0060] Fig.14 This is a detection chromatogram of the impurity-spiked test solution 1 under the chromatographic conditions of Example 1.

[0061] Fig.15 It is the detection chromatogram of the impurity-spiked test solution 2 under the chromatographic conditions of Example 1.

[0062] Fig.16 It is the detection chromatogram of Comparative Example 1.

[0063] Fig.17 This is the detection chromatogram of Test Example 14.

[0064] Fig.18 It is the detection chromatogram of Comparative Example 2. DETAILED DESCRIPTION

[0065] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0066] Unless otherwise defined, the technical terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The experimental reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the raw materials, instruments and equipment used in the following examples, etc., can all be purchased on the market or can be obtained by existing methods; the amounts of the experimental reagents, unless otherwise specified, are the amounts of reagents used in conventional experimental operations; the experimental methods, unless otherwise specified, are all conventional methods.

[0067] The desloratadine and desloratadine oral solution used in the examples of the present invention are both homemade samples, and their preparation prescriptions are the same as the commercially available desloratadine oral solution (trade name: Aerius).

[0068] Example 1

[0069] Prepare solvent: Mix methanol and water (volume ratio 50:50) and set aside.

[0070] Preparation of test solution: Accurately measure an appropriate amount of desloratadine oral solution, add solvent and dilute quantitatively to make a solution containing approximately 0.2 mg of desloratadine per 1 ml.

[0071] Prepare self-control solution: Accurately measure an appropriate amount of the above test solution, dilute with solvent, and make a solution containing approximately 1 μg of desloratadine per 1 ml.

[0072] Preparation of system suitability solution: Accurately measure an appropriate amount of desloratadine reference substance, add propylene glycol to dissolve (dissolve by ultrasound if necessary) and dilute to make a solution containing approximately 1 mg of desloratadine per 1 ml, let stand for 2 hours, as the system suitability solution stock solution; Accurately measure an appropriate amount of system suitability solution stock solution, add solvent for quantitative dilution, to make a solution containing approximately 0.2 mg of desloratadine per 1 ml, as the system suitability solution.

[0073] Chromatographic conditions of HPLC:

[0074] Chromatographic column: Thermo BDS Hypersil C8 column, 4.6 mm × 250 mm, 5 μm;

[0075] Column temperature: 40°C;

[0076] Flow rate: 1.0ml / min;

[0077] Detection wavelength: 280nm

[0078] Mobile phase A was a 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration was 10 ml / L), pH = 2.00, and mobile phase B was a methanol-acetonitrile mixed solution, wherein the volume ratio of methanol to acetonitrile was 50:50.

[0079] The following elution program was used for gradient elution:

[0080]

[0081] Determination method: Pipette the test solution, self-control solution, and system suitability solution, with an injection volume of 40 μl each, and inject them into the above-mentioned high performance liquid chromatograph to determine the impurity content.

[0082] Three batches of test products were tested, and the impurity contents were as follows:

[0083] Impurities(%) Batch No. 1 Batch No. 2 Batch No. 3 Impurity F 0.07 0.06 0.07 Maximum unknown impurity ND ND ND Total Miscellaneous 0.07 0.06 0.07

[0084] ND: Not Detected

[0085] Preparation quality standards: Impurities A, B, C, D, E, F, and G shall not exceed 0.4%, a single unknown impurity shall not exceed 0.4%, and total impurities shall not exceed 1.5%.

[0086] Conclusion: Only impurity F was detected among the related substances of the three batches of test samples, and other impurities were not detected. The test results all met the limit requirements.

[0087] Methodological validation

[0088] The method of the present invention was verified by methodology, which proved that the method of the present invention can achieve the purpose of quality control in the production, storage and use of desloratadine and its preparations.

[0089] Methodological verification (the impurity content was determined using the method of Example 1, and only some impurities were listed)

[0090] Experimental methods:

[0091] (I) Solution preparation:

[0092] Solvent: methanol-water (50:50), i.e. blank solution.

[0093] 20.26 mg of impurity F reference substance and 20.76 mg of impurity G reference substance were placed in different 50 ml volumetric flasks, dissolved with solvent and diluted to the mark, and shaken well to obtain stock solution 1 of each impurity reference substance.

[0094] Each impurity reference substance stock solution 2: Accurately measure 4 ml of each impurity reference substance stock solution 1, place it in different 10 ml volumetric flasks, add solvent to dilute to the scale, shake well, and obtain (concentration is about 160 μg / ml).

[0095] Main component reference substance stock solution 1: Take an appropriate amount of desloratadine reference substance, accurately weigh it (the sample weight is 100.28 mg), put it in a 25 ml volumetric flask, add solvent to dissolve and make up to the scale, shake well, and the main component reference substance stock solution 1 is obtained.

[0096] Main component reference substance stock solution 2: Accurately measure 5 ml of desloratadine reference substance stock solution 1, place it in a 50 ml volumetric flask, add solvent to dilute and make up to the scale, shake well, and the main component reference substance stock solution 2 is obtained.

[0097] Stock solution 1 of each impurity reference substance (Impurities AF): Take appropriate amount of each impurity reference substance of desloratadine, accurately weigh them respectively (Impurity A reference substance 20.73 mg, Impurity B reference substance 20.59 mg, Impurity C reference substance 20.75 mg, Impurity D reference substance 20.56 mg, Impurity E reference substance 20.89 mg, Impurity F reference substance 20.73 mg), place them in different 50 ml volumetric flasks, add solvent to dissolve and make up to the scale, shake well, and obtain.

[0098] Stock solution 1 of each impurity reference substance (impurity G): Accurately weigh 10.28 mg of desloratadine impurity G reference substance, place it in a 25 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and obtain.

[0099] Each impurity reference substance stock solution 2 (impurity AG): accurately measure 4 ml of each impurity reference substance stock solution 1 (impurity AF, impurity G), place in different 10 ml volumetric flasks, add solvent to dilute to the scale, shake well, and obtain (concentration is about 160 μg / ml).

[0100] Each impurity location solution: accurately measure 0.5 ml of impurity reference stock solution 2, place in different 100 ml volumetric flasks, add solvent to dilute to the scale, shake well, and obtain (concentration is about 0.8 μg / ml).

[0101] Main component reference substance stock solution 1 (selectivity and interference): Take an appropriate amount of desloratadine reference substance, accurately weigh it (the sample weight is 20.03 mg), put it in a 5 ml volumetric flask, add solvent to dissolve and make up to the scale, shake well, and obtain.

[0102] Main component positioning solution: Accurately measure 0.5 ml of main component reference stock solution 1, place it in a 10 ml volumetric flask, add solvent to dilute and make up to the scale, shake well, and obtain.

[0103] Blank excipient solution: Take about 1.0290g of anhydrous citric acid, about 2.5227g of sodium citrate, about 210.01g of sorbitol, about 0.6145g of sucralose, about 200.00g of propylene glycol, about 7.0032g of hypromellose, about 0.30g of strawberry flavor and about 0.5016g of disodium edetate respectively, put them in the same 2000ml volumetric flask, dissolve them in water and make up to the scale, shake well, and obtain.

[0104] Main component reference substance stock solution 3: Accurately measure 1 ml of main component reference substance stock solution 1, place it in a 50 ml volumetric flask, add solvent to dilute and make up to the scale, shake well, and the main component reference substance stock solution 3 is obtained.

[0105] Impurity B, impurity A, impurity G and main component quantitative limit solution: accurately measure 1 ml of each impurity reference substance stock solution 2 and 1.25 ml of main component reference substance stock solution 1, respectively, place in a 100 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place in a 20 ml volumetric flask, dilute to the scale with solvent, shake well;

[0106] Impurity E, impurity D, impurity F and impurity C quantitative limit solutions: accurately measure 1 ml of each impurity reference substance stock solution 2 and 1.25 ml of the main component reference substance stock solution 1, respectively, place in a 100 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 5 ml, place in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place in a 10 ml volumetric flask, dilute to the scale with solvent, shake well; at the same time, use it as the detection limit solution of impurity B, impurity A, impurity G and the main component;

[0107] Detection limit solutions of impurity E, impurity D, impurity F and impurity C: accurately measure 1 ml of each impurity reference stock solution 2 and 1.25 ml of the main component reference stock solution 1, place in a 100 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 5 ml, place in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, accurately measure 1 ml, place in a 50 ml volumetric flask, dilute to the scale with solvent, and shake well.

[0108] (II) Experimental results are shown in Table 1

[0109] Table 1 Summary of analytical method validation

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124] The results show that the detection method of the present invention has good system applicability and specificity, and its linearity, accuracy and precision meet the requirements, and it has good durability, which proves that the method is suitable for the detection of related substances in desloratadine raw materials and preparations thereof.

[0125] The impurity spiked desloratadine test solution was used for verification and quantitative investigation

[0126] Preparation of solvent: Same as Example 1.

[0127] Desloratadine raw material test solution: Prepare the system suitability solution as in Example 1.

[0128] Chromatographic conditions: same as in Example 1.

[0129] Prepare impurity spiked test solution I: prepare impurity spiked test solution I with a concentration of 0.2 mg / ml of desloratadine stock solution by adding impurity A, impurity B, impurity C, impurity D, impurity E, impurity F and impurity G reference substances, with the concentrations of impurity A and impurity B being 0.4 μg / ml and the concentrations of the remaining impurities being 0.2 μg / ml).

[0130] Results: Content of desloratadine and impurities in 6 batches of raw materials spiked with test products (%)

[0131]

[0132] The results of determination of desloratadine and impurity contents (%) in 6 batches of desloratadine raw materials are shown in the following table:

[0133]

[0134] In 6 batches of desloratadine raw materials (without spike), the detection limits of impurities were all lower than the negligible limit, while in the raw materials spiked for comparison, all impurities could be detected. It can be seen that the non-spiked method of this application can replace the spiked method.

[0135] Validation, qualitative and quantitative investigation using impurity spiked desloratadine oral solution test solution

[0136] Preparation of solvent: Same as Example 1.

[0137] The chromatographic conditions were the same as in Example 1.

[0138] Chromatographic conditions: same as in Example 1.

[0139] Preparation of impurity spiked test solution 1: Desloratadine oral solution with a concentration of 0.2 mg / ml was prepared by adding impurity A, impurity B, impurity C, impurity D, impurity E, impurity F and impurity G reference substances, and the concentration of each impurity was 0.8 μg / ml).

[0140] Impurity reference solution: Prepare an impurity I reference solution at a concentration of 0.8 μg / ml.

[0141] Impurity spiked test solution 2: a 0.2 mg / ml desloratadine oral solution was prepared by adding impurity I reference substance, with an impurity concentration of 0.8 μg / ml).

[0142] Test results such as Fig.14 As shown, the minimum separation degree of the chromatographic condition, the separation degree of impurity B and the main peak is 1.76, which can achieve effective separation between desloratadine and impurities and between impurities in the desloratadine oral solution. Impurity I was not detected in the desloratadine oral solution.

[0143] Test results such as Fig.15 As shown, only impurity F and added impurity I were detected in desloratadine oral solution, and other impurities such as A, B, C, D, E, and G did not exceed the negligible limit and were not detected.

[0144] The results of the accuracy test of impurity I in desloratadine oral solution are as follows:

[0145]

[0146] From the qualitative analysis of desloratadine oral solution (without spike-in) and the accuracy test using the self-control method and the impurity external standard method in desloratadine oral solution, the recovery ratio was 94%, which is between 80% and 120%. It can be seen that the non-spiked method of the present application can replace the spiked method to detect the oral solution.

[0147] In summary, The validation experiment using impurity spiked desloratadine raw material and oral solution test solution proved that The non-spiked method in this application can replace the spiked method to detect raw materials and oral solutions.

[0148] Test Example: Screening of Chromatographic Conditions of Example 1

[0149] 1. Screening of organic phase

[0150] Experimental Example 1: Chromatographic Condition 1

[0151] Column: Thermo BDS Hypersil C8, 4.6 mm × 250 mm, 5 μm;

[0152] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 2.5, mobile phase B: methanol;

[0153] The gradient elution program was:

[0154]

[0155] Flow rate: 1.0ml / min;

[0156] Column temperature: 30°C;

[0157] Detection wavelength: 280nm;

[0158] Injection volume: 40 μl;

[0159] Prepare solvent: Mix methanol and water (volume ratio 50:50) and set aside;

[0160] Preparation of external standard method reference solution: Use desloratadine reference substance, impurity A reference substance, impurity B reference substance, impurity C reference substance, impurity D reference substance, impurity E reference substance, impurity F reference substance and impurity G reference substance to prepare. The concentration of desloratadine reference substance is 0.2 mg / ml, and the concentration of impurity reference substances is about 0.8 μg / ml.

[0161] Test results such as Figure 1 shown.

[0162] according to Figure 1 As shown, under the chromatographic conditions, impurity A and impurity G, impurity D and impurity F did not achieve baseline separation, and the chromatographic conditions needed to be further adjusted.

[0163] Experimental Example 2: Chromatographic Condition 2

[0164] Mobile phase B: acetonitrile;

[0165] The gradient elution program was:

[0166]

[0167] The other conditions were the same as those in chromatographic condition 1.

[0168] Test results such as Figure 2 shown.

[0169] according to Figure 2 As shown, under the chromatographic conditions, impurity A and impurity G did not achieve baseline separation, and the chromatographic conditions needed to be further adjusted.

[0170] Experimental Example 3: Chromatographic Condition 3

[0171] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 2.5, mobile phase B: methanol-acetonitrile mixed solution (volume ratio 2:3);

[0172] The gradient elution program was:

[0173]

[0174] The other conditions were the same as those in chromatographic condition 1.

[0175] Test results such as Figure 3 shown.

[0176] according to Figure 3 As shown, under the chromatographic conditions, impurity A and impurity G did not achieve baseline separation, and the chromatographic conditions needed to be further adjusted.

[0177] Experimental Example 4: Chromatographic Condition 4

[0178] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 2.5, mobile phase B: methanol-acetonitrile mixed solution (volume ratio 2:3);

[0179] The gradient elution program was:

[0180]

[0181]

[0182] The remaining conditions were the same as those in chromatographic condition 3.

[0183] Test results such as Figure 4 shown.

[0184] according to Figure 4 As shown, the minimum separation degree of the chromatographic conditions is 1.02 for impurity B and the main peak. It can be seen from conditions 1 to 4 that using methanol and acetonitrile as mobile phases, respectively, has a greater impact on the separation of impurities. Therefore, methanol and acetonitrile are mixed in a certain proportion as the organic phase and the optimization is continued.

[0185] 2. Screening of column temperature and pH value of mobile phase A

[0186] Experimental Example 5: Chromatographic Condition 5

[0187] Column temperature: 35 °C;

[0188] The rest of the conditions were the same as those in chromatographic condition 4;

[0189] Test results such as Figure 5 shown.

[0190] according to Figure 5 As shown, the minimum separation degree of the chromatographic conditions, the separation degree between impurity B and the main peak is 1.01, and the chromatographic conditions need to be further adjusted.

[0191] Experimental Example 6: Chromatographic Condition 6

[0192] Mobile phase A: potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L) with a pH value of 3.0;

[0193] Column temperature: 35 °C;

[0194] The rest of the conditions were the same as chromatographic condition 3;

[0195] Test results such as Figure 6 shown.

[0196] according to Figure 6 As shown, under the chromatographic conditions, impurity B and the main peak are not separated by baseline, and the baseline tends to sink, so the chromatographic conditions need to be further adjusted.

[0197] Experimental Example 7: Chromatographic Conditions 7

[0198] Column temperature: 40°C;

[0199] The rest of the conditions were the same as chromatographic condition 6;

[0200] Test results such as Figure 7 shown.

[0201] according to Figure 7 As shown, under the chromatographic conditions, impurity B and the main peak are not separated by baseline, and the baseline tends to sink, so the chromatographic conditions need to be further adjusted.

[0202] Experimental Example 8: Chromatographic Conditions 8

[0203] Mobile phase A: potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L) with a pH value of 2.0;

[0204] The rest of the conditions were the same as chromatographic condition 7;

[0205] Test results such as Figure 8 shown.

[0206] according to Figure 8 As shown, the minimum separation degree under the chromatographic conditions is 1.51 between impurity B and the main peak.

[0207] Combining the above conditions to detect the chromatogram, impurity A and impurity G are sensitive to temperature. Therefore, under the conditions of pH 2.0 and column temperature of 40°C, the mobile phase ratio and gradient were further optimized.

[0208] 3. Screening of mobile phase gradient and organic phase ratio

[0209] Experimental Example 9: Chromatographic Conditions 9

[0210] Column: Thermo BDS Hypersil C8, 4.6 mm × 250 mm, 5 μm;

[0211] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 2.0, mobile phase B: methanol-acetonitrile mixed solution (volume ratio 1:1);

[0212] The gradient elution program was:

[0213]

[0214] Column temperature: 40°C;

[0215] Injection volume: 40 μl;

[0216] Flow rate: 1.0ml / ml;

[0217] Detection wavelength: 280nm;

[0218] Prepare solvent: Mix methanol and water (volume ratio 50:50) and set aside;

[0219] Preparation of external standard method reference solution: Use desloratadine reference substance, impurity A reference substance, impurity B reference substance, impurity C reference substance, impurity D reference substance, impurity E reference substance, impurity F reference substance and impurity G reference substance to prepare. The concentration of desloratadine reference substance is 0.2 mg / ml, and the concentration of impurity reference substances is about 0.8 μg / ml.

[0220] Test results such as Fig. 9 shown.

[0221] according to Fig. 9 As shown, the minimum separation degree under the chromatographic conditions is 1.66 between impurity B and the main peak.

[0222] Experimental Example 10: Chromatographic Conditions 10

[0223] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration is 10 ml / L). pH 2.0, mobile phase B: methanol-acetonitrile mixed solution (volume ratio 2:1);

[0224] The gradient elution program was:

[0225]

[0226] The rest of the conditions were the same as those in chromatographic condition 9;

[0227] Test results such as Fig.10 shown.

[0228] according to Fig.10 As shown, the minimum separation degree under the chromatographic conditions is 1.51 between impurity B and the main peak.

[0229] Experimental Example 11: Chromatographic Conditions 11

[0230] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 2.0, mobile phase B: methanol-acetonitrile mixed solution (volume ratio 1:2);

[0231] The gradient elution program was:

[0232]

[0233] The rest of the conditions were the same as those in chromatographic condition 9;

[0234] Test results such as Fig.11 shown.

[0235] according to Fig.11 As shown, the minimum separation degree under the chromatographic conditions is 1.63 between impurity B and the main peak.

[0236] Experimental Example 12: Chromatographic Conditions 12

[0237] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 2.1;

[0238] The rest of the conditions were the same as those in chromatographic condition 9;

[0239] Test results such as Fig.12 shown.

[0240] according to Fig.12 As shown, the minimum separation degree under the chromatographic conditions is 1.64 between impurity B and the main peak.

[0241] Experimental Example 13: Chromatographic Conditions 13

[0242] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L), pH 1.9;

[0243] The rest of the conditions were the same as those in chromatographic condition 9;

[0244] Test results such as Fig.13 shown.

[0245] according to Fig.13 As shown, the minimum separation degree under the chromatographic conditions is 1.46 between impurity A and impurity G.

[0246] The influence of mobile phase system on chromatographic separation

[0247] Comparative Example 1

[0248] The mobile phase was a trifluoroacetic acid solution of sodium dodecyl sulfate (0.865 g sodium dodecyl sulfate was dissolved in 1000 ml water, and 0.5 ml trifluoroacetic acid was added)-acetonitrile (volume ratio 57:43), isocratic elution was performed, and the chromatographic column was Hypersil C8 4.6 mm*25 cm, 5 μm. Other conditions were the same as those of chromatographic condition 9.

[0249] Test results such as Fig.16 As shown, the impurities are not completely separated.

[0250] Conclusion: By comparing Test Example 9 and Comparative Example 1, it can be seen that the mobile phase system of the present invention can achieve effective separation between desloratadine and impurities and between impurities and the main peak, has good separation effect, and the mobile phase is simple to prepare and has low cost.

[0251] Effect of adding triethylamine on chromatographic separation

[0252] Test Example 14

[0253] Mobile phase A: potassium dihydrogen phosphate solution (containing triethylamine, concentration of 10 ml / L) (pH 2.5);

[0254] Other conditions were the same as those in chromatographic condition 9.

[0255] Test results such as Fig.17 shown.

[0256] Comparative Example 2

[0257] Mobile phase A: potassium dihydrogen phosphate solution (pH 2.5), without triethylamine;

[0258] Other conditions were the same as those in chromatographic condition 9.

[0259] Test results such as Fig.18 shown.

[0260] Conclusion: By comparing Test Example 14 and Comparative Example 2, it can be seen that when the mobile phase A buffer salt is not added with triethylamine, the main peak is broadened and the tailing is serious (tailing factor 10.30), which affects the separation of impurities after the main peak. It can be seen that the addition of triethylamine can significantly improve the tailing phenomenon of the main peak.

[0261] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.

Claims

1. A method for detecting related substances in a desloratadine raw material or a desloratadine preparation, characterized in that: The qualitative and / or quantitative detection is performed by high performance liquid chromatography, and the detection conditions include: Chromatographic column: reverse phase column; Mobile phase: mobile phase A and mobile phase B, wherein the mobile phase A is a phosphate buffer solution, and the mobile phase B is a mixed solution of methanol and acetonitrile for gradient elution.

2. The detection method according to claim 1, characterized in that: The elution conditions: Preferably, the following elution program is used for gradient elution: Preferably, the following elution program is used for gradient elution:

3. The detection method according to claim 2, characterized in that: The mobile phase adopts an isocratic elution program after 35-45 minutes, with mobile phase A 75-85 volume %, mobile phase B 25-15 volume %; preferably, after 40 minutes, the following isocratic elution program is adopted: mobile phase A 75-82 volume %, mobile phase B 25-18 volume %; preferably, after 40 minutes, the following isocratic elution program is adopted:

4. The detection method according to claim 1 or 2, characterized in that: In the mobile phase B, the volume ratio of methanol to acetonitrile is (1-3):(3-1), preferably (1-2):(3-1).

5. The detection method according to claim 1 or 2, characterized in that: The pH value of the phosphate buffer solution is 1.5-2.5, preferably 1.9-2.1; Preferably, the phosphate buffer solution includes one or more of potassium dihydrogen phosphate solution, sodium dihydrogen phosphate solution, dipotassium hydrogen phosphate solution, and disodium hydrogen phosphate solution; Preferably, the concentration of the phosphate buffer solution is 0.005-0.015 mol / L, preferably 0.01 mol / L.

6. The detection method according to claim 1 or 2, characterized in that: The mobile phase A is a mixture of the phosphate buffer solution and an organic amine; Preferably, the organic amine is selected from one or more of triethylamine, tetrabutylammonium hydrogen sulfate, tetrabutylammonium bromide, tetrabutylammonium hydroxide or perfluorotriethylamine; Preferably, the volume ratio of the organic amine to the phosphate buffer solution is (1 ml to 20 ml):1L, preferably 10 ml:1L.

7. The detection method according to claim 1 or 2, characterized in that: The detection conditions also include one or more of the following: Chromatographic column: C8 chromatographic column, C18 chromatographic column or equivalent chromatographic column, preferably with specifications of 4.6 mm × 250 mm, 3 μm to 5 μm, preferably 5 μm; preferably Thermo BDS Hypersil C8 chromatographic column; Column temperature: 30℃~45℃; preferably 38℃~42℃; Flow rate: 0.5ml / min~1.5ml / min; preferably 1.0ml / min; The injection volume is 20 to 60 μl, preferably 30 to 50 μl, and more preferably 40 μl.

8. The detection method according to claim 1 or 2, characterized in that: The related substances in the desloratadine raw material or its preparation include one or more of the following compounds:

9. The detection method according to claim 1 or 2, characterized in that: It also includes preparing one or more of the following solutions: Blank excipient solution: Accurately weigh the excipients in the desloratadine oral solution except desloratadine, and dissolve them in water to make up the volume; Prepare the test solution: accurately measure the desloratadine oral solution, add a solvent to dilute it, and then obtain the test solution. The concentration of desloratadine is 0.01 mg / ml to 2 mg / ml, preferably 0.1 mg / ml to 1 mg / ml, and more preferably 0.2 mg / ml; Prepare the self-control solution: accurately measure the test solution, add solvent to dilute it, and then obtain the self-control solution, wherein the concentration of desloratadine is 0.05-10 μg / ml, preferably 1 μg / ml; Preparation of system suitability solution: accurately weigh desloratadine reference substance, dissolve and dilute with propylene glycol to prepare a solution containing about 0.1 to 10 mg of desloratadine per 1 ml, and place for 0.1 to 24 hours as a system suitability solution stock solution; accurately measure the system suitability solution stock solution, add a solvent for quantitative dilution, and prepare a solution containing about 0.01 mg / ml to 2 mg / ml of desloratadine per 1 ml as a system suitability solution; The solvent is a mixed solution of methanol and water.

10. The detection method according to claim 1 or 2, characterized in that: The detection method uses the principal component self-comparison method without adding a correction factor to calculate the impurity content.